Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Sarcoma, Kaposi 4Leukemia, Lymphocytic, Chronic, B-Cell 2Epstein-Barr Virus Infections 2Cytomegalovirus Infections 2Acquired Immunodeficiency Syndrome 2Sarcoma 1Multi-centric Castleman's Disease 1Lymphoproliferative Disorders 1Lymphoma 1Leukemia 1Immune Reconstitution Inflammatory Syndrome 1Herpes Simplex 1Glioblastoma 1Fatigue Syndrome, Chronic 1Fatigue 1Castleman Disease 1

Interventions

Therapeutics 20Exercise 16Yoga 15Modafinil 12Surveys and Questionnaires 11Psychiatric Rehabilitation 10Methylphenidate 7Acupuncture Therapy 7Therapeutic Touch 6Ultraviolet Therapy 5Educational Status 5Acceptance and Commitment Therapy 5Walking 4Sugars 4Physical Therapy Modalities 4Palliative Care 4Early Intervention, Educational 4Control Groups 4Behavior Therapy 4methyl hydroxyethyl cellulose 3Touch 3Exercise Therapy 3Epoetin Alfa 3Counseling 3Acupressure 3Standard of Care 2Sodium Chloride 2Resistance Training 2Qigong 2Music Therapy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Fatigue × Valganciclovir × Clear all
NCT00478465 2022-05-27

Valganciclovir (Valcyte) for Chronic Fatigue Syndrome Patients Who Have Elevated Antibody Titers Against Human Herpes Virus 6 (HHV-6)and Epstein-Barr Virus (EBV)

Stanford University

Phase 1/2 Completed
30 enrolled

Fatigue, Herpes Simplex, Fatigue Syndrome, Chronic, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡